Inflammatory and immune cells in lung tissue

Inflammatory and immune cells in lung tissue represent a complex cellular milieu consisting of resident and recruited leukocytes, including alveolar macrophages, neutrophils, T-lymphocytes, B-lymphocytes, eosinophils, and dendritic cells. These cells are fundamental to the lung's defense mechanism, facilitating the clearance of pathogens and maintaining homeostasis through the secretion of cytokines and chemokines (Hussell & Bell, 2014, Nature Reviews Immunology). In pathological states such as asthma, COPD, and ARDS, these cells become chronically activated or inappropriately recruited, leading to persistent inflammation, airway remodeling, and impaired gas exchange (Barnes, 2008, Nature Reviews Immunology). Therapeutic intervention often involves broad-spectrum immunosuppressants like corticosteroids or targeted biologics that inhibit specific cell-surface markers or signaling molecules within this population (Chung, 2015, European Respiratory Review). While this category is not a single molecular target, it serves as the functional site for numerous pharmacological agents aimed at modulating the pulmonary immune response. Monitoring these cell populations via bronchoalveolar lavage or biopsy is a common practice in clinical research to assess disease progression and treatment efficacy.

Other names

Lung immune cellsPulmonary inflammatory infiltrateAlveolar leukocytesLung-resident immune cellsPulmonary immune microenvironment

Pharmacological agents modulate these cells by inhibiting pro-inflammatory signaling pathways (e.g., NF-kB, JAK/STAT), blocking cytokine receptors (e.g., IL-5R, IL-4R), or preventing cellular recruitment and activation in the lung parenchyma and airways.